(Reuters) -AbbVie said that the U.S. Food and Drug Administration approved its drug for complicated intra-abdominal infections on Friday.
AbbVie and co-developer Pfizer’s drug, Emblaveo, is approved in combination with an antibiotic medication for patients 18 years and older with such infections.
Intra-abdominal infections (IAIs) are a group of infections that occur in the abdominal cavity. They can range from uncomplicated appendicitis to more serious conditions where the infection spreads from the pancreas.
AbbVie said the drug will be available for commercial use in the U.S. in the third quarter of 2025.
AbbVie holds the rights to commercialize the therapy in the U.S. and Canada, with Pfizer responsible for its commercialization in all other areas.
(Reporting by Christy Santhosh in Bengaluru; Editing by Alan Barona)
Comments